The Future is Now: Evolving Standards of Care in MIBC & la/mUC
TumorBoardTuesday MIBC Clinical Case Convo
Yüksel Ürün, MD & Emre Yekedüz, MD | 07/29/2025

Post-survey, Evaluation, & Credit Claim

In order to receive credit for this activity, you must read the front matter, view the activity, complete the post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. Where are you in your career?

Medical Oncologist

Surgical Oncologist

Radiation Oncologist

Pathologist

Other MD/DO

Fellow/Trainee

APP

PharmD

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. In the EV-103 Cohort H eval neoadj EV monotx in cis-inelig pts w/ #MIBC, 50% of pts achieved path downstaging. What was the pCR rate?

• 21%

• 36%

• 51%

• 66%

Question Title

* 4. ➡️🧐65yo pt w/ MIBC
➡️ECOG PS 2
➡️CrCl 39 mL/minute

🗳️According to the criteria developed by Jiang et al, would this patient be considered cisplatin-eligible in the neoadj setting❓

Yes

EVALUATION FORM

Question Title

* 5. Approximately how many patients with bladder cancer do you currently see each week?

1-3

4-6

7-9

10+

I do not directly provide care for patients with bladder cancer

Question Title

* 6. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
Analyze the role of antibody-drug conjugates and their potential to address unmet needs for additional therapy options in earlier stages of urothelial carcinoma.	Analyze the role of antibody-drug conjugates and their potential to address unmet needs for additional therapy options in earlier stages of urothelial carcinoma. Strongly agree	Analyze the role of antibody-drug conjugates and their potential to address unmet needs for additional therapy options in earlier stages of urothelial carcinoma. Agree	Analyze the role of antibody-drug conjugates and their potential to address unmet needs for additional therapy options in earlier stages of urothelial carcinoma. Disagree	Analyze the role of antibody-drug conjugates and their potential to address unmet needs for additional therapy options in earlier stages of urothelial carcinoma. Strongly disagree

Question Title

* 7. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
The faculty were effective in presenting the material	The faculty were effective in presenting the material Strongly agree	The faculty were effective in presenting the material Agree	The faculty were effective in presenting the material Neutral	The faculty were effective in presenting the material Disagree	The faculty were effective in presenting the material Strongly disagree
Information in this activity is relevant to my clinical practice	Information in this activity is relevant to my clinical practice Strongly agree	Information in this activity is relevant to my clinical practice Agree	Information in this activity is relevant to my clinical practice Neutral	Information in this activity is relevant to my clinical practice Disagree	Information in this activity is relevant to my clinical practice Strongly disagree
The activity increased my knowledge on this topic	The activity increased my knowledge on this topic Strongly agree	The activity increased my knowledge on this topic Agree	The activity increased my knowledge on this topic Neutral	The activity increased my knowledge on this topic Disagree	The activity increased my knowledge on this topic Strongly disagree
The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.)	The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.) Strongly agree	The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.) Agree	The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.) Neutral	The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.) Disagree	The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.) Strongly disagree
The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity)	The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity) Strongly agree	The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity) Agree	The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity) Neutral	The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity) Disagree	The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity) Strongly disagree

Question Title

* 8. Please rate your level of agreement by selecting the appropriate rating:
The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Was fair, balanced, objective, and free of commercial bias	Was fair, balanced, objective, and free of commercial bias Strongly agree	Was fair, balanced, objective, and free of commercial bias Agree	Was fair, balanced, objective, and free of commercial bias Neutral	Was fair, balanced, objective, and free of commercial bias Disagree	Was fair, balanced, objective, and free of commercial bias Strongly disagree

Question Title

* 9. Based upon your participation in this activity, do you intend to change your practice behavior?

I plan to implement changes in my practice based on the information presented

My current practice has been reinforced by the information presented

I need more information before I will change my practice

Not applicable to my scope of practice

Question Title

* 10. How confident are you that you will be able to make your intended changes?

Very confident

Somewhat confident

Unsure

Not confident

Question Title

* 11. Which of the following do you anticipate will be the primary barrier to implementing these changes? (check all that apply):

Formulary restrictions

Time constraints

System constraints

Patient adherence/compliance

Insurance/financial issues

Lack of interprofessional team support

Treatment related adverse events

None

Other (please specify)

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 13. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

* 14. I certify that I have participated in the continuing education activity entitled, "MIBC Clinical Case Convo" and claim 1.0 AMA PRA Category 1 Credit^TM.

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4-6 weeks to receive your certificate.

For information about the certification of this program, please contact Partners for Advancing Clinical Education (PACE) at contactus@partnersed.com.

The Future is Now: Evolving Standards of Care in MIBC & la/mUCTumorBoardTuesday MIBC Clinical Case ConvoYüksel Ürün, MD & Emre Yekedüz, MD | 07/29/2025***Post-survey, Evaluation, & Credit Claim***

Question Title

* 1. Where are you in your career?

Question Title

* 2. What is your community of practice?

Question Title

* 3. In the EV-103 Cohort H eval neoadj EV monotx in cis-inelig pts w/ #MIBC, 50% of pts achieved path downstaging. What was the pCR rate?

Question Title

* 4. ➡️🧐65yo pt w/ MIBC➡️ECOG PS 2➡️CrCl 39 mL/minute🗳️According to the criteria developed by Jiang et al, would this patient be considered cisplatin-eligible in the neoadj setting❓

Question Title

* 5. Approximately how many patients with bladder cancer do you currently see each week?

Question Title

* 6. Upon completion of this activity, I am able to:

Question Title

* 7. Please indicate the extent of your agreement with the following statements:

Question Title

* 8. Please rate your level of agreement by selecting the appropriate rating:The content presented:

Question Title

* 9. Based upon your participation in this activity, do you intend to change your practice behavior?

Question Title

* 10. How confident are you that you will be able to make your intended changes?

Question Title

* 11. Which of the following do you anticipate will be the primary barrier to implementing these changes? (check all that apply):

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 13. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 14. I certify that I have participated in the continuing education activity entitled, "MIBC Clinical Case Convo" and claim 1.0 AMA PRA Category 1 CreditTM.

The Future is Now: Evolving Standards of Care in MIBC & la/mUC
TumorBoardTuesday MIBC Clinical Case Convo
Yüksel Ürün, MD & Emre Yekedüz, MD | 07/29/2025

Post-survey, Evaluation, & Credit Claim

* 4. ➡️🧐65yo pt w/ MIBC
➡️ECOG PS 2
➡️CrCl 39 mL/minute

🗳️According to the criteria developed by Jiang et al, would this patient be considered cisplatin-eligible in the neoadj setting❓

* 8. Please rate your level of agreement by selecting the appropriate rating:
The content presented:

* 13. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

* 14. I certify that I have participated in the continuing education activity entitled, "MIBC Clinical Case Convo" and claim 1.0 AMA PRA Category 1 Credit^TM.